Brokers Set Expectations for Palomar FY2026 Earnings

Key Points

• DOWLING & PARTN projected Palomar’s FY2026 earnings at $8.53 per share, below the current consensus estimate of $9.02. The firm also forecast FY2027 EPS of $9.82.
• Analyst sentiment has been mixed, with recent downgrades from Zacks Research, Wall Street Zen, and Weiss Ratings, while JPMorgan cut its price target to $150 but kept an overweight rating. Overall, MarketBeat shows a Moderate Buy consensus with a target price of $147.75.
• Palomar’s latest quarterly results beat earnings expectations, reporting $2.31 EPS versus $2.17 expected, and revenue rose 59.7% year over year. However, the company’s stock has been trading well below its 52-week high, and several insiders recently sold shares.

Palomar Holdings, Inc. (NASDAQ:PLMR - Free Report) - Analysts at DOWLING & PARTN issued their FY2026 earnings estimates for Palomar in a research note issued to investors on Wednesday, May 20th. DOWLING & PARTN analyst N. Iacoviello forecasts that the company will post earnings of $8.53 per share for the year. The consensus estimate for Palomar's current full-year earnings is $9.02 per share. DOWLING & PARTN also issued estimates for Palomar's FY2027 earnings at $9.82 EPS.

Other equities analysts also recently issued research reports about the stock. Zacks Research downgraded shares of Palomar from a "strong-buy" rating to a "hold" rating in a research note on Friday, May 15th. JPMorgan Chase & Co. reduced their price objective on shares of Palomar from $160.00 to $150.00 and set an "overweight" rating for the company in a research note on Tuesday. Wall Street Zen downgraded shares of Palomar from a "buy" rating to a "hold" rating in a research note on Sunday, March 1st. Weiss Ratings downgraded shares of Palomar from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Thursday, May 7th. Finally, Evercore initiated coverage on shares of Palomar in a research note on Monday, February 9th. They issued an "outperform" rating and a $150.00 price objective for the company. Four analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $147.75.

Palomar Stock Performance

Shares of NASDAQ:PLMR opened at $109.45 on Thursday. The company has a market capitalization of $2.90 billion, a price-to-earnings ratio of 15.24 and a beta of 0.49. Palomar has a 52 week low of $107.51 and a 52 week high of $175.85. The company has a quick ratio of 0.49, a current ratio of 0.49 and a debt-to-equity ratio of 0.31. The firm has a 50 day moving average of $120.21 and a 200 day moving average of $124.47.

Palomar (NASDAQ:PLMR - Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $2.31 EPS for the quarter, topping analysts' consensus estimates of $2.17 by $0.14. The company had revenue of $278.94 million during the quarter, compared to the consensus estimate of $557.79 million. Palomar had a net margin of 20.11% and a return on equity of 22.62%. Palomar's revenue for the quarter was up 59.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.87 earnings per share.

Hedge Funds Weigh In On Palomar

Large investors have recently made changes to their positions in the business. Geneos Wealth Management Inc. acquired a new position in shares of Palomar during the fourth quarter worth $32,000. Kestra Advisory Services LLC purchased a new stake in shares of Palomar during the fourth quarter valued at $33,000. Rockefeller Capital Management L.P. grew its holdings in shares of Palomar by 81.5% during the fourth quarter. Rockefeller Capital Management L.P. now owns 294 shares of the company's stock valued at $40,000 after buying an additional 132 shares during the last quarter. Clearstead Advisors LLC grew its holdings in shares of Palomar by 31.0% during the third quarter. Clearstead Advisors LLC now owns 397 shares of the company's stock valued at $46,000 after buying an additional 94 shares during the last quarter. Finally, Parallel Advisors LLC grew its holdings in shares of Palomar by 638.3% during the first quarter. Parallel Advisors LLC now owns 443 shares of the company's stock valued at $53,000 after buying an additional 383 shares during the last quarter. 90.25% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CEO Mac Armstrong sold 3,500 shares of the company's stock in a transaction on Monday, March 23rd. The stock was sold at an average price of $120.58, for a total transaction of $422,030.00. Following the transaction, the chief executive officer directly owned 339,888 shares of the company's stock, valued at approximately $40,983,695.04. This represents a 1.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, President Jon Christianson sold 3,000 shares of the company's stock in a transaction on Tuesday, April 7th. The stock was sold at an average price of $125.00, for a total value of $375,000.00. Following the transaction, the president directly owned 62,919 shares in the company, valued at approximately $7,864,875. The trade was a 4.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 18,634 shares of company stock worth $2,318,111. Insiders own 3.70% of the company's stock.

Palomar Company Profile

Palomar Holdings, Inc NASDAQ: PLMR is a specialty insurance holding company focused on providing medical stop-loss coverage and related administrative services to self-funded employer health plans in the United States. The firm operates through two primary business segments—Medical Stop-Loss and Specialty Program Management—to deliver tailored risk protection and comprehensive program administration.

In its Medical Stop-Loss segment, Palomar underwrites excess and aggregate stop-loss policies designed to shield self-insured employers from catastrophic medical claims that exceed pre-determined retention levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.